Showing 4371-4380 of 8791 results for "".
- Laura Bush Named SDPA’s Board Presidenthttps://practicaldermatology.com/news/laura-bush-named-sdpas-board-president/2461847/Georgia-based dermatology physician assistant Laura Bush is the new president of the Society of Dermatology Physician Assistant's (SDPA) Board of Directors. Bush, a DermPA with Fayette Area Dermatology in Fayetteville, Georgia, will serve a one-year term leading the nine-membe
- Regular Moisturizer Use May Reduce Signs of Aging Skin, Plus More Research from Estée Lauderhttps://practicaldermatology.com/news/regular-moisturizer-use-may-reduce-signs-of-aging-skin-on-the-face-skin-aging-plus-more-wcd-presented-research-from-estee-lauder/2461846/Regular use of moisturizer can mitigate skin aging, according to research presented by The Estée Lauder Companies Inc. at the 25th World Congress of Dermatology in Singapore. In an evaluator-blinded, randomized, 6-month longitudinal study of 160 women, a
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- RVL Launches New Prescription E-commerce Platformhttps://practicaldermatology.com/news/rvl-launches-new-prescription-e-commerce-platform/2461844/RVL Pharmaceuticals is launching a prescription e-commerce platform. ELEVATE is a secure subscription platform that allows both providers and patients to purchase RVL products. The platform comprises RVL-initiated auto refills and unlocks ad
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- WCD News: Spesolimab Prevents GPP Flareshttps://practicaldermatology.com/news/wcd-news-spesolimab-prevents-gpp-flares/2461841/Spesolimab reduced the risk of generalized pustular psoriasis (GPP) flares flares by 84% over 48 weeks compared to placebo, according to late-breaking data from the EFFISAYIL™ 2 trial presebted at the at the 25th World Congress of Dermatology (WCD) in Singapore. Fur
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itc
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w
- Biosimilar News: Coherus Launches Humira Biosimilar at $995 per Carton in U.S.https://practicaldermatology.com/news/biosimilar-news-coherus-launches-humira-biosimilar-at-995-per-carton-in-us/2461834/Coherus BioSciences, Inc’s YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors. This cost represents a discount of more than 85% to Humira (adalimumab), currently price
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the